Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982423 · ClinicalTrials.gov registry record · Phase 1
The Effects of Decreasing the Lasix Dose on the Cardiorenal System
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00982423: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00982423 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00982423, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The investigators' objective is to define the effects of decreasing the furosemide dose on heart, kidney and humoral function in people with compensated heart failure and kidney dysfunction and also in people with compensated heart failure without kidney dysfunction. Secondly, to define the humoral activation in both groups.
Interventions
- DRUG Furosemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982423
The ClinicalTrials.gov registry entry for NCT00982423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Furosemide is the first listed.
NCT00982423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982423 about?
NCT00982423 is a clinical study titled "The Effects of Decreasing the Lasix Dose on the Cardiorenal System". The investigators' objective is to define the effects of decreasing the furosemide dose on heart, kidney and humoral function in people with compensated heart failure and kidney dysfunction and also in people with compensated heart failure without kidney dysfunction. Secondly, to define the humoral ...
What is the current status of trial NCT00982423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00982423?
The interventions under investigation include: Furosemide (DRUG).
Who is sponsoring clinical trial NCT00982423?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.